Determining the Efficacy & Value of Immunotherapy on the Likelihood of

Status Completed

Clinical Trial Summary

Peanut allergy is known to cause severe anaphylactic reactions.The goal of this proposal is to produce a new treatment that would benefit young subjects who have recently been diagnosed with peanut allergy by lowering the risk of anaphylactic reactions (desensitization), and changing the peanut-specific immune response in subjects who have peanut allergy (tolerance).

Clinical Trial Description

Peanut allergy is known to cause severe anaphylactic reactions. Compared with other food allergies, it tends to be more persistent and its prevalence seems to be rising. Currently, there is no proven treatment other than strict avoidance. We are attempting to decrease the risk of anaphylaxis on accidental ingestion by desensitizing subjects to peanut using peanut mucosal immunotherapy (PMIT) more commonly called oral immunotherapy (OIT). We are also studying the effect of PMIT on the peanut-specific immune response to determine if tolerance to peanut protein will develop. Based on our preliminary work and recent studies supporting the importance of early oral exposure in tolerance induction, we propose that early treatment of peanut allergy with PMIT will be safe and effective. Children ages 9 to 36 months with peanut allergy will be randomized to receive high or low dose PMIT using peanut flour. Subjects will undergo desensitization on the first day and then increase the doses gradually to a maintenance dose. Doses will be taken daily at home except for dose increases which will be done on the research unit. Subjects will undergo a double-blinded, placebo-controlled food challenge (DBPCFC) if challenge criteria are met. Subjects passing the first challenge will stop PMIT and repeat the DBPCFC to assess tolerance. Outcome variables of interest include response to oral food challenges (OFC), skin prick testing, peanut specific serum immunoglobin E (IgE), immunoglobin G (IgG), and immunoglobin G4 (IgG4) and stool immunoglobin A (IgA), T and B cell responses, quality of life, and adverse events. As secondary and exploratory outcomes, these longitudinal results will be compared between high and low dose PMIT groups and controls using appropriate statistical analysis. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00932828
Study type	Interventional
Source	University of North Carolina, Chapel Hill
Contact
Status	Completed
Phase	Phase 2
Start date	June 22, 2009
Completion date	February 1, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01904604` - Peanut Epicutaneous Phase II Immunotherapy Clinical Trial	Phase 2
Enrolling by invitation	`NCT04885959` - The Effects of Traditional Asian Diet on Gut Microbiome and Metabolome in Healthy Volunteers and Pregnancy on Subsequent Infant's Allergy Development	N/A
Recruiting	`NCT03974555` - Epidemiological Investigation and Cohort Study on Food Allergy in Children Aged 3 to 6 Years in Wenzhou and Taizhou Urban Areas
Recruiting	`NCT05177744` - Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease
Completed	`NCT01420705` - Bacille Calmette-Guérin (BCG) Vaccine and Atopy	N/A
Completed	`NCT00850668` - Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults	Phase 1
Withdrawn	`NCT00736112` - Food Allergy - Tubes - Adenoids (FATA) Trial	N/A
Active, not recruiting	`NCT00298337` - Use of Probiotic Bacteria in Prevention of Allergic Disease in Children 1999-2008	Phase 2/Phase 3
Completed	`NCT03693456` - Food Allergy Diagnostic Test Response to Previous Oral Challenge Response	N/A
Completed	`NCT00461097` - Oral Immunotherapy for Childhood Egg Allergy	Phase 2
Completed	`NCT02606721` - Food Allergy Challenge Diagnostic Study
Active, not recruiting	`NCT02457416` - Take Away Food Allergy; Inducing Tolerance in Children Allergic to Peanut	N/A
Completed	`NCT02825069` - Study on the Induction of Food Tolerance in Babies	N/A
Completed	`NCT02350660` - Oral Immunotherapy for Peanut and Mammalian Meat Allergies	N/A
Completed	`NCT01084174` - A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy	Phase 1/Phase 2
Completed	`NCT00597675` - Oral Immunotherapy for Peanut Allergy (PMIT)	Phase 2
Completed	`NCT01373242` - Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance	Phase 1/Phase 2
Completed	`NCT00578656` - An Interventional Study of Milk Allergy	Phase 0
Completed	`NCT00356174` - An Observational Study of Childhood Food Allergy	N/A
Completed	`NCT02304991` - FARE Peanut SLIT and Early Tolerance Induction	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study — DEVIL

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms